A late-breaking presentation at the American Society of Hematology (ASH) 2025 meeting revealed promising phase 3 findings for ...
"It’s important for us to think about ITP as any other autoimmune disorder. When it’s flaring, fatigue is associated." -- Michelle Sholzberg, MDCM, MSc, St. Michael’s Hospital, Toronto The study, ...
An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address ...
An experimental monoclonal antibody called ianalumab had promising results for more than half of patients with primary immune thrombocytopenia enrolled in a phase 3 trial, according to data published ...
Several areas of discordance were observed, including contributing causes for delay in diagnosis, with patients perceiving extended wait times as a significant contributing factor. Patients were ...
Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopeniaNovel treatment targets BTK through multi-immune ...
Immune thrombocytopenia (ITP) doesn’t have a cure and can be unpredictable. There are two main types of ITP, acute and chronic. The acute type usually lasts six months or less. It’s more common in ...
STOCKHOLM, Dec. 8, 2019 /PRNewswire/ -- Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), presented results from an online survey highlighting disease ...
HealthDay on MSN
Experimental Drug Provides Lasting Relief For Bleeding Condition
Ianalumab, a monoclonal antibody, helped patients with immune thrombocytopenia (ITP) maintain safe platelet counts without ...
Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard therapy went longer without a bleeding episode that needed urgent treatment or ...
The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune thrombocytopenia, according to randomized phase 3 study results.The combination ...
The COVID-19 pandemic has reshaped daily life around the world. For many people living with chronic health conditions, the pandemic has been especially concerning. COVID-19 is a contagious respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback